159 related articles for article (PubMed ID: 36288869)
21. Advances of biphenyl small-molecule inhibitors targeting PD-1/PD-L1 interaction in cancer immunotherapy.
Chen R; Yuan D; Ma J
Future Med Chem; 2022 Jan; 14(2):97-113. PubMed ID: 34870447
[TBL] [Abstract][Full Text] [Related]
22. Discovery of Novel and Highly Potent Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer Treatment.
Cheng B; Wang W; Niu X; Ren Y; Liu T; Cao H; Wang S; Tu Y; Chen J; Liu S; Yang X; Chen J
J Med Chem; 2020 Dec; 63(24):15946-15959. PubMed ID: 33264007
[TBL] [Abstract][Full Text] [Related]
23. Discovery of 1,3,4-oxadiazole derivatives as potential antitumor agents inhibiting the programmed cell death-1/programmed cell death-ligand 1 interaction.
Fang L; Tian J; Zhang K; Zhang X; Liu Y; Cheng Z; Zhou J; Zhang H
Bioorg Med Chem; 2021 Sep; 46():116370. PubMed ID: 34481337
[TBL] [Abstract][Full Text] [Related]
24. Preparation and Bioevaluation of
Hu X; Lv G; Hua D; Zhang N; Liu Q; Qin S; Zhang L; Xi H; Qiu L; Lin J
Mol Pharm; 2023 Aug; 20(8):4228-4235. PubMed ID: 37409670
[TBL] [Abstract][Full Text] [Related]
25. Discovery of Novel PD-L1 Small-Molecular Inhibitors with Potent
Liu L; Zhang H; Hou J; Zhang Y; Wang L; Wang S; Yao Z; Xie T; Wen X; Xu Q; Dai L; Feng Z; Zhang P; Wu Y; Sun H; Liu J; Yuan H
J Med Chem; 2024 Mar; 67(6):4977-4997. PubMed ID: 38465588
[TBL] [Abstract][Full Text] [Related]
26. Design, Synthesis, and Evaluation of
OuYang Y; Gao J; Zhao L; Lu J; Zhong H; Tang H; Jin S; Yue L; Li Y; Guo W; Xu Q; Lai Y
J Med Chem; 2021 Jun; 64(11):7646-7666. PubMed ID: 34037385
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis, and structure-activity relationship of PD-1/PD-L1 inhibitors with a benzo[d]isoxazole scaffold.
Huang X; Chen H; Dai X; Xu M; Wang K; Feng Z
Bioorg Med Chem Lett; 2021 Nov; 52():128403. PubMed ID: 34610423
[TBL] [Abstract][Full Text] [Related]
28. A combined approach of structure-based virtual screening and NMR to interrupt the PD-1/PD-L1 axis: Biphenyl-benzimidazole containing compounds as novel PD-L1 inhibitors.
Donati G; Viviano M; D'Amore VM; Cipriano A; Diakogiannaki I; Amato J; Tomassi S; Brancaccio D; Russomanno P; Di Leva FS; Arosio D; Seneci P; Taliani S; Magiera-Mularz K; Musielak B; Skalniak L; Holak TA; Castellano S; La Pietra V; Marinelli L
Arch Pharm (Weinheim); 2024 Mar; 357(3):e2300583. PubMed ID: 38110703
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of galectin-3 augments the antitumor efficacy of PD-L1 blockade in non-small-cell lung cancer.
Zhang H; Liu P; Zhang Y; Han L; Hu Z; Cai Z; Cai J
FEBS Open Bio; 2021 Mar; 11(3):911-920. PubMed ID: 33455075
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy.
Orafaie A; Sadeghian H; Bahrami AR; Rafatpanah H; Matin MM
Bioorg Med Chem; 2021 Jan; 30():115951. PubMed ID: 33360579
[TBL] [Abstract][Full Text] [Related]
31. Design, Synthesis, and Antitumor Activity Evaluation of 2-Arylmethoxy-4-(2,2'-dihalogen-substituted biphenyl-3-ylmethoxy) Benzylamine Derivatives as Potent PD-1/PD-L1 Inhibitors.
Zhang H; Zhou S; Plewka J; Wu C; Zhu M; Yu Q; Musielak B; Wang X; Awadasseid A; Magiera-Mularz K; Wu Y; Zhang W
J Med Chem; 2023 Aug; 66(15):10579-10603. PubMed ID: 37496104
[TBL] [Abstract][Full Text] [Related]
32. A d-peptide-based oral nanotherapeutic modulates the PD-1/PD-L1 interaction for tumor immunotherapy.
Liu D; Wang J; You W; Ma F; Sun Q; She J; He W; Yang G
Front Immunol; 2023; 14():1228581. PubMed ID: 37529049
[TBL] [Abstract][Full Text] [Related]
33. Molecular hybridization used to design and synthesize neo-tanshinlactone derivatives as PD-1/PD-L1 inhibitors.
Zhang M; Liu J; Wang Y; Wang P; Morris-Natschke S; Lee KH
Bioorg Med Chem; 2022 Jan; 54():116579. PubMed ID: 34954618
[TBL] [Abstract][Full Text] [Related]
34. Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1.
Lee CH; Bae JH; Choe EJ; Park JM; Park SS; Cho HJ; Song BJ; Baek MC
Theranostics; 2022; 12(5):1971-1987. PubMed ID: 35265193
[TBL] [Abstract][Full Text] [Related]
35. Symmetry-based ligand design and evaluation of small molecule inhibitors of programmed cell death-1/programmed death-ligand 1 interaction.
Kawashita S; Aoyagi K; Yamanaka H; Hantani R; Naruoka S; Tanimoto A; Hori Y; Toyonaga Y; Fukushima K; Miyazaki S; Hantani Y
Bioorg Med Chem Lett; 2019 Sep; 29(17):2464-2467. PubMed ID: 31351692
[TBL] [Abstract][Full Text] [Related]
36. Development and functional analysis of an anticancer T-cell medicine with immune checkpoint inhibitory ability.
Fujiwara K; Shigematsu K; Tachibana M; Okada N
IUBMB Life; 2020 Aug; 72(8):1649-1658. PubMed ID: 32255257
[TBL] [Abstract][Full Text] [Related]
37. Discovery of phenyl-linked symmetric small molecules as inhibitors of the programmed cell death-1/programmed cell death-ligand 1 interaction.
Wu Y; Zhang Y; Guo Y; Pan Z; Zhong S; Jin X; Zhuang W; Chen S; Gao J; Huang W; Dong X; Che J
Eur J Med Chem; 2021 Nov; 223():113637. PubMed ID: 34147746
[TBL] [Abstract][Full Text] [Related]
38. Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse.
Ashizawa T; Iizuka A; Nonomura C; Kondou R; Maeda C; Miyata H; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Katano I; Ito M; Akiyama Y
Clin Cancer Res; 2017 Jan; 23(1):149-158. PubMed ID: 27458246
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and pharmacological evaluation of novel resorcinol biphenyl ether analogs as small molecule inhibitors of PD-1/PD-L1 with benign toxicity profiles for cancer treatment.
Cao H; Cheng B; Liu T; Chen J
Biochem Pharmacol; 2021 Jun; 188():114522. PubMed ID: 33741334
[TBL] [Abstract][Full Text] [Related]
40. Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature.
Kopalli SR; Kang TB; Lee KH; Koppula S
Recent Pat Anticancer Drug Discov; 2019; 14(2):100-112. PubMed ID: 30370857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]